Table 2 Univariate survival for GMS according to TNM, MMR status, adjuvant chemotherapy and location of primary cancer (N = 783).
From: The Glasgow Microenvironment Score and risk and site of recurrence in TNM I–III colorectal cancer
Group GMS category | N | Cancer-specific survival | Overall survival | ||||||
|---|---|---|---|---|---|---|---|---|---|
5-year CSS (%; SE) | Events (N = 201) | HR (95% CI) | p | 5-year OS (%; SE) | Events (N = 477) | HR (95% CI) | p | ||
Full cohort | Trend | <0.001 | Trend | <0.001 | |||||
0 | 132 | 89 (3) | 19 | 1.0 (reference) | 75 (4) | 67 | 1.0 (reference) | ||
1 | 501 | 78 (2) | 122 | 1.88 (1.16–3.06) | 0.01 | 63 (2) | 310 | 1.40 (1.08-1.82) | 0.01 |
2 | 149 | 61 (4) | 60 | 3.72 (2.22–6.24) | <0.001 | 48 (4) | 100 | 1.97 (1.44–2.69) | <0.001 |
TNM I–II | Trend | 0.003 | Trend | 0.09 | |||||
0 | 103 | 89 (3) | 13 | 1.0 (reference) | 74 (4) | 51 | 1.0 (reference) | ||
1 | 314 | 87 (2) | 50 | 1.35 (0.73–2.48) | 0.34 | 69 (3) | 183 | 1.26 (0.92–1.72) | 0.15 |
2 | 63 | 75 (6) | 19 | 2.89 (1.42–5.85) | 0.003 | 58 (6) | 38 | 1.59 (1.04–2.42) | 0.03 |
TNM III | Trend | 0.007 | Trend | 0.006 | |||||
0 | 29 | 90 (6) | 6 | 1.0 (reference) | 79 (8) | 16 | 1.0 (reference) | ||
1 | 187 | 63 (4) | 72 | 2.24 (0.97–5.14) | 0.06 | 54 (4) | 127 | 1.67 (0.99–2.81) | 0.05 |
2 | 86 | 50 (6) | 41 | 3.36 (1.42–7.91) | 0.006 | 41 (5) | 62 | 2.32 (1.33–4.03) | 0.003 |
MMR proficient | Trend | <0.001 | Trend | 0.007 | |||||
0 | 92 | 93 (3) | 15 | 1.0 (reference) | 75 (5) | 47 | 1.0 (reference) | ||
1 | 362 | 80 (2) | 86 | 1.62 (0.94–2.81) | 0.08 | 63 (3) | 223 | 1.38 (1.01–1.89) | 0.045 |
2 | 95 | 65 (5) | 38 | 3.21 (1.76–5.84) | <0.001 | 49 (5) | 62 | 1.84 (1.26–2.70) | 0.002 |
MMR deficient | Trend | 0.024 | Trend | 0.02 | |||||
0 | 19 | 95 (5) | 1 | 1.0 (reference) | 68 (11) | 12 | 1.0 (reference) | ||
1 | 68 | 75 (5) | 34 | 3.81 (0.90–16.11) | 0.07 | 60 (6) | 50 | 1.21 (0.65–2.29) | 0.55 |
2 | 34 | 59 (9) | 19 | 6.72 (1.53–29.58) | 0.01 | 38 (8) | 28 | 2.23 (1.13–4.41) | 0.02 |
No adjuvant chemo | Trend | <0.001 | Trend | 0.001 | |||||
0 | 111 | 87 (3) | 18 | 1.0 (reference) | 70 (4) | 63 | 1.0 (reference) | ||
1 | 375 | 78 (2) | 88 | 1.59 (0.96–2.65) | 0.07 | 61 (3) | 252 | 1.33 (1.01–1.75) | 0.046 |
2 | 99 | 63 (5) | 40 | 3.33 (1.91–5.82) | <0.001 | 47 (5) | 72 | 1.88 (1.34–2.64) | <0.001 |
Adjuvant chemo | Trend | 0.007 | Trend | 0.002 | |||||
0 | 21 | 100 (0) | 1 | 1.0 (reference) | 100 (0) | 4 | 1.0 (reference) | ||
1 | 126 | 76 (4) | 34 | 6.82 (0.93–49.86) | 0.06 | 71 (4) | 58 | 3.33 (1.21–9.20) | 0.02 |
2 | 49 | 58 (7) | 19 | 11.54 (1.54–86.27) | 0.02 | 51 (7) | 27 | 5.30 (1.84–15.26) | 0.002 |
Colon cancer | Trend | <0.001 | Trend | 0.002 | |||||
0 | 93 | 90 (3) | 14 | 1.0 (reference) | 77 (4) | 47 | 1.0 (reference) | ||
1 | 359 | 79 (2) | 85 | 1.78 (1.01–3.13) | 0.046 | 64 (3) | 225 | 1.40 (1.03–1.92) | 0.04 |
2 | 102 | 61 (5) | 40 | 3.54 (1.92–6.51) | <0.001 | 47 (5) | 68 | 1.95 (1.34–2.83) | <0.001 |
Rectal cancer | Trend | 0.004 | Trend | 0.04 | |||||
0 | 39 | 89 (5) | 5 | 1.0 (reference) | 69 (7) | 20 | 1.0 (reference) | ||
1 | 142 | 75 (4) | 37 | 2.16 (0.85–5.50) | 0.11 | 63 (4) | 85 | 1.38 (0.84–2.24) | 0.20 |
2 | 47 | 61 (8) | 20 | 4.17 (1.56–11.13) | 0.004 | 51 (7) | 32 | 2.02 (1.15–3.54) | 0.015 |
